Article Text
PDF
Statistics from Altmetric.com
Q In patients with asthma, how effective is omalizumab, a recombinant humanised monoclonal antibody, in reducing asthma exacerbations and steroid use?
Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★☆☆☆ Respirology ★★★★★★☆
METHODS
Data sources:
searching Cochrane Airways Group trials register, scanning the reference lists of relevant studies and review articles, reviewing abstracts presented at leading respiratory society meetings, contacting pharmaceutical companies manufacturing anti-immunoglobulin E (IgE) formulations, and contacting experts in the field.
Study selection and assessment:
randomised controlled trials comparing anti-IgE at any dose or route with placebo or conventional treatments in children and adults with chronic asthma.
Outcomes:
reduction or termination of steroid use and asthma exacerbations (hospital admissions, emergency department visits, days lost from work or school, unscheduled physician visits, and increase in medication).
MAIN RESULTS
8 blinded, placebo controlled trials of …
Footnotes
-
Abstract and commentary also appear in ACP Journal Club.
-
For correspondence: Dr S Walker, National Respiratory Training Centre, Warwick, UK. s.walkernrtc.org.uk
-
Source of funding: Garfield Weston Foundation UK.